1. Home
  2. COOK vs PLRX Comparison

COOK vs PLRX Comparison

Compare COOK & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Traeger Inc.

COOK

Traeger Inc.

HOLD

Current Price

$33.66

Market Cap

83.7M

ML Signal

HOLD

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

HOLD

Current Price

$1.30

Market Cap

81.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COOK
PLRX
Founded
1985
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.7M
81.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
COOK
PLRX
Price
$33.66
$1.30
Analyst Decision
Hold
Hold
Analyst Count
5
4
Target Price
$53.00
$2.67
AVG Volume (30 Days)
97.6K
485.4K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.97
EPS
N/A
N/A
Revenue
$559,520,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$1.09
52 Week High
$35.56
$1.95

Technical Indicators

Market Signals
Indicator
COOK
PLRX
Relative Strength Index (RSI) 72.74 52.19
Support Level $0.92 $1.12
Resistance Level $35.56 $1.38
Average True Range (ATR) 2.54 0.07
MACD -0.39 0.00
Stochastic Oscillator 82.05 72.92

Price Performance

Historical Comparison
COOK
PLRX

About COOK Traeger Inc.

Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Share on Social Networks: